dr. kluger on toxicities associated with immunotherapies
Published 10 years ago • 79 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:45
dr. kluger on the toxicity profile of concurrent nivolumab and ipilimumab
-
1:27
dr. kluger on how immunotherapies are changing the treatment of melanoma
-
1:37
dr. kluger on the changing landscape of immunotherapies for the treatment of melanoma
-
1:30
dr. kluger on toxicity of nivolumab/ ipilimumab for advanced melanoma
-
1:03
dr. kluger on the difference between blocking pd-1 and pd-l1 in melanoma
-
1:28
dr. kluger on the changes and challenges of treating melanoma
-
14:01
asco® 2024 insights: dr. harriet kluger
-
14:42
managing toxicities associated with immune-checkpoint inhibitors
-
1:06
dr. kluger on systemic management of melanoma with brain metastases
-
52:27
immunotherapy/checkpoint inhibitor, targeted immunotherapy drugs 5/2/18
-
1:21
dr. kluger on immunotherapy in melanoma
-
1:33
dr. wolchok on the management of side effects associated with immunotherapies
-
1:06
understanding the unique adverse events associated with immunotherapy agents
-
4:45
immunotherapies and immune-related toxicities
-
0:51
monitor toxicities when treating breast cancer with immunotherapy
-
2:22
immunotherapy toxicities and checkpoint inhibitor therapy
-
56:25
dissecting toxicities of immune checkpoint inhibitors with dr. douglas johnson, m.d., msci
-
2:12
dr. wolchok on combining targeted and immunotherapies
-
15:04
debate: targeting the immune system with checkpoint inhibitors - single drug therapy